CELC stock forecast, quote, news & analysis

Key Takeaways

• Celcuity Inc. is being driven primarily by late-stage clinical and regulatory milestones tied to gedatolisib.
• Recent weeks brought positive Phase 3 updates, expanded trial plans, and continued launch preparation ahead of a key U.S. Food and Drug Administration (FDA) decision.
• Analyst sentiment has remained broadly constructive, with several firms reiterating Buy-equivalent ratings after the company’s May updates.
• The stock has also shown how sensitive biotech valuations can be to conference data releases, regulatory timing, and shifting expectations.
• Liquidity remains an important support, with Celcuity reporting cash, cash equivalents, and short-term investments of $387.1 million at the end of the first quarter.

Current Market Snapshot

Celcuity Inc. has remained one of the more closely watched small-cap biotechnology names in recent weeks as investors weigh a strong clinical narrative against the usual event risk that comes with drug-development stocks. The company’s market profile is now centered on whether gedatolisib can translate encouraging trial results into regulatory progress and, eventually, commercialization. That has kept CELC highly responsive to company updates, analyst commentary, and conference-related readouts. In the latest market cycle, the stock has reflected both optimism around its lead program and the volatility that often appears when expectations become elevated.

Trending AI Robots

Tickeron’s Trending AI Robots page offers a curated view of the platform’s strongest current ideas rather than a full dump of every strategy available. Tickeron says it has 351 total AI bots on the platform, while the trending section highlights 25 selected bots judged to be the most promising for current market conditions. These bots span stocks, exchange-traded funds (ETFs), and crypto, and they differ by timeframe, volatility profile, technical or fundamental approach, and risk-management design. The page also organizes bots across 60-minute, 15-minute, and 5-minute styles, showing that traders can choose between slower and more active strategies. For investors exploring systematic tools, this section is a practical place to compare the most relevant options first.

Recent Developments Driving CELC Price Action

The biggest driver of CELC in the past 30 days has been Celcuity’s May 14, 2026 first-quarter update, which paired financial results with a major clinical and strategic update. The company said the PIK3CA mutant-type cohort in its Phase 3 VIKTORIA-1 study met its primary endpoint, with gedatolisib plus fulvestrant and palbociclib showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS, the length of time a patient lives without disease worsening) versus alpelisib plus fulvestrant. Celcuity also said the gedatolisib doublet showed a statistically significant and clinically meaningful PFS benefit, with no new safety signals reported. For biotech investors, positive pivotal-trial data in a large breast cancer setting is often the clearest catalyst for valuation re-rating, and that update strengthened the core bull case around the company’s lead asset.

The same May 14 release also confirmed that detailed VIKTORIA-1 data would be presented in a late-breaking oral session at the 2026 American Society of Clinical Oncology (ASCO) meeting on June 2, 2026, and that Celcuity intends to submit those data to the FDA in the third quarter as a supplemental New Drug Application (sNDA, an application to expand an already filed drug submission). That matters because CELC was already approaching an important regulatory milestone: the FDA had previously accepted the New Drug Application (NDA, New Drug Application) for gedatolisib in HR-positive (hormone receptor-positive), HER2-negative (human epidermal growth factor receptor 2-negative), PIK3CA wild-type advanced breast cancer and assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 17, 2026. Together, the May updates reinforced the view that Celcuity is moving from a pure development-stage story toward a regulatory and launch story.

Celcuity also used the May 14 announcement to expand VIKTORIA-2, its first-line breast cancer program, to include a second study in endocrine-sensitive patients. At the same time, the company disclosed that development of a subcutaneous formulation of gedatolisib is under way and that it had submitted its first patent application covering that formulation. While these updates are not as immediate as an FDA decision, they helped support sentiment by showing management is thinking beyond a single initial indication and building a broader lifecycle strategy around the drug.

On the financial side, Celcuity reported that net cash used in operations rose to $55.1 million in the first quarter, while cash, cash equivalents, and short-term investments stood at $387.1 million at quarter end. Management said those resources, along with debt-facility drawdowns, are expected to finance operations through 2027. That funding outlook is important because it reduces near-term financing pressure, a common concern in biotech. Analyst reactions after the May updates were generally supportive: H.C. Wainwright raised its target to $185 on May 18, Wells Fargo raised its target to $183 on May 15, and Stifel raised its target to $175 on May 15, while Citizens later reiterated a Market Outperform rating with a $160 target and highlighted ASCO as a key venue ahead of the July regulatory date. Those actions helped reinforce positive sentiment, even as the stock remained vulnerable to sharp swings as investors recalibrated expectations around conference data and approval odds.

2026 Outlook and Key Factors to Monitor

For the rest of 2026, the central issue for Celcuity is execution. Investors will be watching the July 17, 2026 PDUFA date for gedatolisib in the PIK3CA wild-type advanced breast cancer setting, along with the company’s planned third-quarter sNDA submission tied to the PIK3CA mutant cohort. If regulatory momentum continues, attention is likely to shift toward launch readiness, payer access, physician adoption, and how gedatolisib is positioned against existing PI3K-alpha (phosphoinositide 3-kinase alpha) targeted therapies and CDK4/6 inhibitors (cyclin-dependent kinase 4 and 6 inhibitors).

Beyond the immediate approval timeline, investors should also monitor VIKTORIA-2 enrollment and design execution, progress on the subcutaneous formulation, and the company’s spending profile as commercialization investments continue. Celcuity’s cash position provides flexibility, but operating burn remains meaningful, so capital discipline will stay relevant. More broadly, CELC’s market outlook will also depend on how investors value single-asset or lead-asset biotech companies in a risk-sensitive rate environment. In short, 2026 is shaping up as a transition year in which clinical success must increasingly be matched by regulatory precision and commercial preparation.

Disclaimer

“The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.” Disclaimers and Limitations